Bing

SEARCH HISTORY

AstraZeneca plc (LON:AZN)‘s stock had its “outperform” rating reissued by research analysts at BNP Paribas in a report released on Tuesday. They currently have a GBX 5,800 ($88.69) price objective on the biopharmaceutical company’s stock.
sleekmoney.com · 6 hours ago
AstraZeneca plc
In-depth coverage >
AstraZeneca plc (LON:AZN)‘s stock had its “reduce” rating reiterated by Kepler Capital Markets in a research note issued on Tuesday. They currently have a GBX 3,700 ($56.57) price objective on the biopharmaceutical company’s stock. Kepler Capital ...
Ticker Report · 5 hours ago
AstraZeneca plc
AstraZeneca (NYSE: AZN) and MedImmune, the Company’s global biologics research and development arm, provided an update on the progress of their combination-focused immuno-oncology pipeline at an investor science event at the American Society …
Stockhouse · 10 minutes ago
More from Bing News
AZN.US). They remain the two largest firms in the pharmaceutical sector of the London Stock Exchange, so that thinking still lingers in most investors' minds. But GSK's CEO Andrew Witty has taken his company in a …
Yahoo Finance UK and Ireland · 6 hours ago
GlaxoSmithKline plc
AstraZeneca plc (LON:AZN)‘s stock had its “buy” rating reissued by analysts at Citigroup Inc. in a research report issued to clients and investors on Wednesday. They currently have a GBX 5,400 ($83.57) price target on the stock. Citigroup Inc.’s ...
Mideast Times · 5/27/2015
Clovis' rucaparib made a strong claim Saturday to unseat AstraZeneca's Lynparza as the most effective PARP inhibitor treatment for a genetically defined segment of previously-treated ovarian cancer patients. Must Read: Warren Buffet's Top 10 Stock Buys …
The Street · ByAdam Feuerstein · 1 day ago
AstraZeneca currently carries a Zacks Rank #3 (Hold). Juno Therapeutics is a better-ranked stock in the health care sector carrying a Zacks Rank #1 (Strong Buy).
Yahoo Finance · 18 hours ago
AstraZeneca
Recall that AstraZeneca CEO Pascal Soriot promised shareholders $45 ... short of the $600 million in annual sales Citi thought it could deliver. Meanwhile, AZ's stock now sits at £43.73 per share, the FT points out, compared with Pfizer's rejected £ ...
FiercePharma · ByTracy Staton · 5/27/2015
AstraZeneca plc (AZN - Analyst Report) and its global biologics research and development arm, MedImmune, presented encouraging abstracts of data from their MEDI4736 (anti-PD-L1 monoclonal antibody) combination-based immuno-oncology portfolio at …
ZACKS · 20 hours ago
He was promoted to this position last December, and three months ago, was offered company shares as part of a stock incentive plan and he agreed ... he informed Bristol-Myers that he was taking a job with …
The Wall Street Journal · 21 hours ago
Bristol Myers
Related Searches